Navigation Links
Bioheart Makes Breakthrough in Critical Limb Ischemia Therapy with Stem Cells Obtained from Fat Tissue
Date:12/21/2009

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
2. Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
3. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
4. Bioheart, Inc. Announces Additional Funding Support
5. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
8. Bioheart, Inc. Announces Results of Annual Meeting
9. Bioheart, Inc., Announces Management Change
10. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
11. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... Dec. 7 CVF Technologies,Corporation,s (OTC Bulletin Board: CNVT) ... a customer in Beijing, China for a,Biofiltair odor control ... China to approximately $500,000 (Cdn) and is the third ... "We are pleased that our technology was accepted on ...
... 7 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, will report,financial results for ... on Monday, December 10, 2007 at 4:30 p.m. ET., ... (888) 408-9532 or,(706) 679-5064 or by accessing the web ...
... Products for the Long-Term Care Channel, ... Inc., wholly owned subsidiary of Millennium Biotechnologies,Group, ... that the initial,$200,000.00 monthly shipment from Millennium ... under the previously announced $20,000,000,Five- year exclusive ...
Cached Biology Technology:CVF Technologies Corporation's Holding - BIOREM Announces 3rd Order from China 2Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 2Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order 3
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., the leading ... that pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred years ago, ... a meeting place for peoples from different continents. This study ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Institute for Biological Studies discovered that cells co-opted the ... protect the integrity of chromosomes. This finding solves for ... puzzled scientists. , The natural ends of chromosomes look ... repair machinery is designed to fix. But mending chromosome ...
... very earliest genetic changes involved in the development of lung ... mouse that develops the disease in much the same way ... 1 issue of Cancer Research, open the door to the ... the very first signs of lung cancer, when the possibility ...
... pathogenic fungi as model systems for understanding fungal diseases, ... offers insight into how carbon dioxide (CO2) governs the ... different environments and invade the human body, and they ... utilize evolutionarily conserved enzymes to control the growth and ...
Cached Biology News:Normal chromosome ends elicit a limited DNA damage response 2Building a better mouse model of lung cancer: FHIT counts 2Building a better mouse model of lung cancer: FHIT counts 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3
Anti-Mouse Macrophages (Metallophillic), Purified (Clone MOMA-1) (rat IgG2a)...
Request Info...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Biology Products: